Drug intelligence / Profile preview

BWC6096

Development stage: Preclinical
Lead developer: Bugworks Research
Modality: Small Molecules
Administration: Oral

Overview

BWC6096 is a small molecule inhibitor of cyclin-dependent kinase 7 (CDK7) under development by Bugworks Research. It is designed to target transcriptionally addicted and difficult-to-treat tumors. By inhibiting CDK7, BWC6096 modulates oncogenic transcription and cell-cycle progression, offering a targeted therapeutic approach. The drug is currently in the lead generation (preclinical) stage of development for the treatment of various solid tumors, including triple-negative breast cancer, ovarian cancer, prostate cancer, lung cancer, and gastrointestinal cancers.

Targets

CDK7

Beyond the preview

Go deeper on BWC6096.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BWC6096.

Explore the full profile